Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hyupjin gets South Korean rights to Pharming's Ruconest

Executive Summary

Private Korean pharmaco Hyupjin Corp. has licensed Korean marketing rights to Pharming Group NV’s (unmet medical needs) Ruconest (recombinant human C1 inhibitor) for acute attacks of hereditary angioedema (HAE).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies